Studies have shown significant changes in gene expression (e.g. S100A8 mediator) and pre-mRNA splicing in MDS patients with SF3B1-K700E mutations, resulting in the upregulation of pro-inflammatory signaling pathways (65). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.